Novo Nordisk (NVO) announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use has adopted a positive opinion for an update of the Ozempic label to reflect data ...

Novo Nordisk has also filed for a label expansion in the US, and a decision is expected in the first half of 2025.

Novo Nordisk announced on Thursday that a key European Medicines Agency committee has backed a label update for weight-loss drug Ozempic to include the reduction of kidney disease risk.

Novo Nordisk (NYSE: NVO) and AstraZeneca (NASDAQ: AZN) are among the largest companies in the pharmaceutical industry. Both have generally produced strong financial results in 2024, but one wouldn ...

GlobalData has named heart failure as the next disease to feel the sales-boosting power of GLP-1 drugs. The analysts expect ...

Novo Nordisk has received European approval for a new indication of its drug, Ozempic. The European Medicines Agency (EMA) has authorized a label expansion to include the treatment of chronic ...

(RTTNews) - Novo Nordisk A/S (NVO), Thursday announced that the European Medicines Agency's Committee for Medicinal Products for Human Use or CHMP has supported label update for weight-loss drug ...

Novo Nordisk said the European Union’s drug regulator supports a label expansion of its Ozempic diabetes drug to reflect its potential to lower the risk of conditions related to kidney disease ...

Both companies are longtime leaders in the pharmaceutical industry and have been making breakthroughs and delivering ...